The group wants to improve on its own Welireg in a new phase 3 trial.
ApexOnco Front Page
Recent articles
Replimune gets a second chance, while Sarclisa could go subcutaneous.
An actinium-based backup and Werner helicase inhibitor are notable absences.
But the Astra/Daiichi ADC stumbles in lung cancer.
First-in-human listings bring a bispecific and yet another in vivo Car-T.
The company is starting four new pivotal trials this year.
The company quietly deprioritises AlphaMedix.
Cafelkibart’s entry into phase 3 is of note to Coherus.
